{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:00:37Z","timestamp":1790791237640,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1476-4598-13-185","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T21:02:48Z","timestamp":1407358968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma"],"prefix":"10.1186","volume":"13","author":[{"given":"Yoshinori","family":"Imura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetatsu","family":"Outani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Wakamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutaro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Myoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhito","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Naka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,7]]},"reference":[{"key":"1387_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/1097-0142(197011)26:5<1029::AID-CNCR2820260510>3.0.CO;2-R","volume":"26","author":"FM Enzinger","year":"1970","unstructured":"Enzinger FM: Epithelioid sarcoma. A sarcoma simulating a granuloma or carcinoma. Cancer. 1970, 26: 1029-1041.","journal-title":"Cancer"},{"key":"1387_CR2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.22037","volume":"107","author":"SA de Visscher","year":"2006","unstructured":"de Visscher SA, van Ginkel RJ, Wobbes T, Veth RP, Ten Heuvel SE, Suurmeijer AJ, Hoekstra HJ: Epithelioid sarcoma: still an only surgically curable disease. Cancer. 2006, 107: 606-612.","journal-title":"Cancer"},{"key":"1387_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/BF02523657","volume":"7","author":"AJ Spillane","year":"2000","unstructured":"Spillane AJ, Thomas JM, Fisher C: Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma. Ann Surg Oncol. 2000, 7: 218-225.","journal-title":"Ann Surg Oncol"},{"key":"1387_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00000478-198504000-00001","volume":"9","author":"DR Chase","year":"1985","unstructured":"Chase DR, Enzinger FM: Epithelioid sarcoma: diagnosis, prognostic indicators, and treatment. Am J Surg Pathol. 1985, 9: 241-263.","journal-title":"Am J Surg Pathol"},{"key":"1387_CR5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S0025-6196(11)63000-0","volume":"71","author":"AC Halling","year":"1996","unstructured":"Halling AC, Wollen PC, Pritchard DJ, Vlasak R, Nascimento AG: Epithelioid sarcoma: a clinicopathologic review of 55 cases. Mayo Clin Med. 1996, 71: 636-642.","journal-title":"Mayo Clin Med"},{"key":"1387_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/35077225","volume":"411","author":"P Blume-Jensen","year":"2001","unstructured":"Blume-Jensen P, Hunter T: Oncogenic kinase signaling. Nature. 2001, 411: 355-365.","journal-title":"Nature"},{"key":"1387_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002, 2: 489-501.","journal-title":"Nat Rev Cancer"},{"key":"1387_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/28212","volume":"394","author":"I Versteege","year":"1998","unstructured":"Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A, Delattre O: Truncating mutations of hSNF5\/INI1 in aggressive paediatric cancer. Nature. 1998, 394: 203-206.","journal-title":"Nature"},{"key":"1387_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/path.2103","volume":"211","author":"F Bourdeaut","year":"2007","unstructured":"Bourdeaut F, Freneaux P, Thuille B, Lellouch-Tubiana A, Nicolas A, Pierron G, Sainte-Rose C, Bergeron C, Bouvier R, Rialland X, Laurence V, Michon J, Sastre-Garau X, Delattre O: hSNF5\/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol. 2007, 211: 323-330.","journal-title":"J Pathol"},{"key":"1387_CR10","first-page":"1038","volume":"10","author":"J Darr","year":"2013","unstructured":"Darr J, Klochendler A, Isaac S, Eden A: Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1\/Snf5-mediated tumorigenesis. Oncogene. 2013, 10: 1038","journal-title":"Oncogene"},{"key":"1387_CR11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/PAS.0b013e3181882c54","volume":"33","author":"JL Hornick","year":"2009","unstructured":"Hornick JL, Dal Cin P, Fletcher CD: Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol. 2009, 33: 542-550.","journal-title":"Am J Surg Pathol"},{"key":"1387_CR12","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1158\/0008-5472.CAN-04-3050","volume":"65","author":"P Modena","year":"2005","unstructured":"Modena P, Lualdi E, Facchinetti , Galli L, Teixeira MR, Pilotti S, Sozzi G: SMARCB1\/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcoma. Cancer Res. 2005, 65: 4012-4019.","journal-title":"Cancer Res"},{"key":"1387_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/1756-0500-6-305","volume":"6","author":"Y Imura","year":"2013","unstructured":"Imura Y, Naka N, Outani H, Yasui H, Takenaka S, Hamada K, Ozaki R, Kaya M, Yoshida K, Morii E, Myoui A, Yoshikawa H: A novel angiomatoid epithelioid sarcoma cell line, Asra-EPS, forming tumors with large cysts containing hemorrhagic fluid in vivo. BMC Res Notes. 2013, 6: 305","journal-title":"BMC Res Notes"},{"key":"1387_CR14","first-page":"51","volume":"7","author":"C Helson","year":"1995","unstructured":"Helson C, Melamed M, Braverman S, Traganos F, Preti R, Helson L: VA-ES-BJ: an epithelioid sarcoma cell line. Int J Oncol. 1995, 7: 51-56.","journal-title":"Int J Oncol"},{"key":"1387_CR15","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-11-2123","volume":"18","author":"F Meric-Bernstam","year":"2012","unstructured":"Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J: PIK3CA\/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012, 18: 1777-1789.","journal-title":"Clin Cancer Res"},{"key":"1387_CR16","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/sj.onc.1201341","volume":"15","author":"SM Metcalfe","year":"1997","unstructured":"Metcalfe SM, Canman CE, Milner J, Morris RE, Goldman S, Kastan MB: Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells. Oncogene. 1997, 15: 1635-1642.","journal-title":"Oncogene"},{"key":"1387_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/JCO.2011.35.6329","volume":"30","author":"SP Chawla","year":"2012","unstructured":"Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D\u2019Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD: Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012, 30: 78-84.","journal-title":"J Clin Oncol"},{"key":"1387_CR18","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1200\/JCO.2012.45.5766","volume":"31","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY: Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013, 31: 2485-2492.","journal-title":"J Clin Oncol"},{"key":"1387_CR19","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66: 1500-1508.","journal-title":"Cancer Res"},{"key":"1387_CR20","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1158\/0008-5472.CAN-12-1319","volume":"72","author":"AL Ho","year":"2012","unstructured":"Ho AL, Vasudeva SD, Lae M, Saito T, Barbashina V, Antonescu CR, Ladanyi M, Schwartz GK: PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res. 2012, 72: 4515-4525.","journal-title":"Cancer Res"},{"key":"1387_CR21","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1172\/JCI28984","volume":"117","author":"H Zhang","year":"2007","unstructured":"Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ: PDGFRs are critical for PI3K\/Akt activation and negatively regulated by mTOR. J Clin Invest. 2007, 117: 730-738.","journal-title":"J Clin Invest"},{"key":"1387_CR22","doi-asserted-by":"publisher","first-page":"e33379","DOI":"10.1371\/journal.pone.0033379","volume":"7","author":"QL Li","year":"2012","unstructured":"Li QL, Gu FM, Wang Z, Jiang JH, Yao LQ, Tan CJ, Huang XY, Ke AW, Dai Z, Fan J, Zhou J: Activation of PI3K\/AKT and MAPK pathway through a PDGFR\u03b2-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. PLoS One. 2012, 7: e33379","journal-title":"PLoS One"},{"key":"1387_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/0092-8674(95)90534-0","volume":"81","author":"TF Franke","year":"1995","unstructured":"Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN: The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 1995, 81: 727-736.","journal-title":"Cell"},{"key":"1387_CR24","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1128\/MCB.17.3.1595","volume":"17","author":"G Kulik","year":"1997","unstructured":"Kulik G, Klippel A, Weber MJ: Antiapototic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 1997, 17: 1595-1606.","journal-title":"Mol Cell Biol"},{"key":"1387_CR25","doi-asserted-by":"publisher","first-page":"25203","DOI":"10.1074\/jbc.M201598200","volume":"277","author":"Q Zeng","year":"2002","unstructured":"Zeng Q, Chen S, You Z, Yang F, Carey TE, Saims D, Wang CY: Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. J Biol Chem. 2002, 277: 25203-25208.","journal-title":"J Biol Chem"},{"key":"1387_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s004280050175","volume":"432","author":"C Kuhnen","year":"1998","unstructured":"Kuhnen C, Tolnay E, Steinau HU, Voss B, Muller KM: Expression of c-Met receptor and hepatocyte growth factor\/scatter factor in synovial sarcoma and epithelioid sarcoma. Virchows Arch. 1998, 432: 337-342.","journal-title":"Virchows Arch"},{"key":"1387_CR27","first-page":"7926","volume":"63","author":"K Jankowski","year":"2003","unstructured":"Jankowski K, Kucia M, Wysoczynski M, Reca R, Zhao D, Trzyna E, Trent J, Peiper S, Zembala M, Ratajczak J, Houghton P, Janowska-Wieczorek A, Ratajczak MZ: Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 2003, 63: 7926-7935.","journal-title":"Cancer Res"},{"key":"1387_CR28","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1158\/1078-0432.CCR-11-0193","volume":"17","author":"KE Torres","year":"2011","unstructured":"Torres KE, Zhu QS, Bill K, Lopez G, Ghadimi MP, Xie X, Young ED, Liu J, Nguyen T, Bolshakov S, Belousov R, Wang S, Lahat G, Liu J, Hernandez B, Lazar AJ, Lev D: Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011, 17: 3943-3955.","journal-title":"Clin Cancer Res"},{"key":"1387_CR29","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1158\/0008-5472.CAN-09-1121","volume":"70","author":"IJ Davis","year":"2010","unstructured":"Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE: Identification of the tyrosine kinase c-Met and its legand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res. 2010, 70: 639-645.","journal-title":"Cancer Res"},{"key":"1387_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0092-8674(00)81780-8","volume":"95","author":"V Stambolic","year":"1998","unstructured":"Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW: Negative regulation of PKB\/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998, 95: 29-39.","journal-title":"Cell"},{"key":"1387_CR31","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-11-1157","volume":"17","author":"X Liu","year":"2011","unstructured":"Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS, Behshad E, Wynn R, Li Y, Boer J, Diamond S, He C, Xu M, Zhuo J, Yao W, Newton RC, Scherle PA: A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011, 17: 7127-7138.","journal-title":"Clin Cancer Res"},{"key":"1387_CR32","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008, 118: 3065-3074.","journal-title":"J Clin Invest"},{"key":"1387_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00280-008-0796-5","volume":"63","author":"K Foster","year":"2009","unstructured":"Foster K, Wang Y, Zhou D, Wright C: Dependence on PI3K\/Akt signaling for malignant rhabdoid tumor cell survival. Cancer Chemother Phamacol. 2009, 63: 783-791.","journal-title":"Cancer Chemother Phamacol"},{"key":"1387_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1042\/BJ20070309","volume":"406","author":"A Arcaro","year":"2007","unstructured":"Arcaro A, Doepfner KT, Boller D, Guerreiro AS, Shalaby T, Jackson SP, Schoenwaelder SM, Delattre O, Grotzer MA, Fischer B: Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. Biochem J. 2007, 406: 57-66.","journal-title":"Biochem J"},{"key":"1387_CR35","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1158\/1535-7163.MCT-13-0005","volume":"12","author":"M Brenca","year":"2013","unstructured":"Brenca M, Rossi S, Lorenzetto E, Piccinin E, Piccinin S, Rossi FM, Giuliano A, Dei Tos AP, Maestro R, Modena P: SMARCB1\/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJ. Mol Cancer Ther. 2013, 12: 1060-1072.","journal-title":"Mol Cancer Ther"},{"key":"1387_CR36","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1371\/journal.pmed.0050008","volume":"5","author":"TF Cloughesy","year":"2008","unstructured":"Cloughesy TF, Yoshimoto K, Nqhiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL: Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008, 5: e8","journal-title":"PLoS Med"},{"key":"1387_CR37","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrm1261","volume":"4","author":"C Birchmeier","year":"2003","unstructured":"Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003, 4: 915-925.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1387_CR38","first-page":"739","volume":"10","author":"R Ferracini","year":"1995","unstructured":"Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini P, Cremona O, Campanacci M, Comoglio PM: The Met\/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene. 1995, 10: 739-749.","journal-title":"Oncogene"},{"key":"1387_CR39","first-page":"89","volume":"74","author":"J Cortner","year":"1995","unstructured":"Cortner J, Vande Woude GF, Rong S: The Met-HGF\/SF autocrine signaling mechanism is involved in sarcomagenesis. EXS. 1995, 74: 89-121.","journal-title":"EXS"},{"key":"1387_CR40","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/j.1440-1827.1998.tb03834.x","volume":"48","author":"T Fukuda","year":"1998","unstructured":"Fukuda T, Ichimura E, Shinozaki T, Sano T, Kashiwabara K, Oyama T, Nakajima T, Nakamura T: Coexpression of HGF and c-Met\/HGF receptor in human bone and soft tissue tumors. Pathol Int. 1998, 48: 757-762.","journal-title":"Pathol Int"},{"key":"1387_CR41","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1158\/0008-5472.CAN-11-3760","volume":"72","author":"KM Joo","year":"2012","unstructured":"Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Gu Kang B, Kang YJ, Lathia JD, Cheong KH, Song PH, Kim H, Seol HJ, Kong DS, Lee JI, Rich JN, Lee J, Nam DH: MET signaling regulates glioblastoma stem cells. Cancer Res. 2012, 72: 3828-3838.","journal-title":"Cancer Res"},{"key":"1387_CR42","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1158\/0008-5472.CAN-11-3490","volume":"72","author":"F De Bacco","year":"2012","unstructured":"De Bacco F, Casanova E, Medico E, Pellegatta S, Orzan F, Albano R, Luraghi P, Reato G, D\u2019Ambrosio A, Porrati P, Patane M, Maderna E, Pollo B, Comoglio PM, Finocchiaro G, Boccaccio C: The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res. 2012, 72: 4537-4550.","journal-title":"Cancer Res"},{"key":"1387_CR43","first-page":"5911","volume":"61","author":"G Dong","year":"2001","unstructured":"Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C: Hepatocyte growth factor\/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 2001, 61: 5911-5918.","journal-title":"Cancer Res"},{"key":"1387_CR44","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1200\/JCO.2010.34.0570","volume":"29","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller JH: Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011, 29: 3307-3315.","journal-title":"J Clin Oncol"},{"key":"1387_CR45","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","volume":"31","author":"DC Smith","year":"2013","unstructured":"Smith DC, Smith MR, Sweeney C, Elfiky AA, Loqothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schoffski P, Scheffold C, Weitzman AL, Hussain M: Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013, 31: 412-419.","journal-title":"J Clin Oncol"},{"key":"1387_CR46","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1158\/1535-7163.MCT-08-0627","volume":"8","author":"Y Li","year":"2009","unstructured":"Li Y, Guessous F, DiPierro C, Zhang Y, Mudrick T, Fuller L, Johnson E, Marcinkiewicz L, Engelhardt M, Kefas B, Schiff D, Kim J, Abounader R: Interactions between PTEN and the c-MET pathway in glioblastoma and implications for therapy. Mol Cancer Ther. 2009, 8: 376-385.","journal-title":"Mol Cancer Ther"},{"key":"1387_CR47","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1158\/1078-0432.CCR-11-0660","volume":"17","author":"X Xie","year":"2011","unstructured":"Xie X, Ghadimi MP, Young ED, Belousov R, Zhu QS, Liu J, Lopez G, Colombo C, Peng T, Reynoso D, Hornick JL, Lazar AJ, Lev D: Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin Cancer Res. 2011, 17: 5901-5912.","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-13-185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:21:53Z","timestamp":1630545713000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-13-185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,7]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1387"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-13-185","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,7]]},"assertion":[{"value":"22 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"185"}}